Acute, Multiple-Dose Dermal and Genetic Toxicity of Nu-3: A Novel Antimicrobial Agent

Table 3

Hematological analysis of 28-day dermal toxicity study of Nu-3 in rats.

Hematological parameters

Nu-3*

Saline

7

14

21

28

35

42

7

14

21

28

35

42 (days)

WBC (10^9/L)

13.36 ± 12.1

15.3 ± 18.4

11.82 ± 2.8

12.48 ± 9.1

13.00 ± 6.8

17.00 ± 27

11.14 ± 3.0

14.57 ± 13.9

12.52 ± 3.9

12.13 ± 4.6

13.00 ± 17

17.50 ± 3.3

RBC (10^12/L)

6.85 ± 0.6

11.36 ± 0.9

9.78 ± 1.8

6.93 ± 0.1

6.07 ± 0.1

9.24 ± 1.1

6.70 ± 1.3

11.7 ± 1.4

9.97 ± 2.8

6.92 ± 0.1

6.71 ± 0.1

10.11 ± 1.9

HGB (g/L)

128.57 ± 51

206.33 ± 37

171.50 ± 18

133.67 ± 43

120.00 ± 12

203.00 ± 67

122.29 ± 27

205.33 ± 21

173.83 ± 17

132.0 ± 6

129.0 ± 12

216.0 ± 22

HCT (%)

35.53 ± 8.82

58.75 ± 50.8

49.85 ± 42.2

36.00 ± 3.6

31.8 ± 0.3

49.10 ± 22.5

34.4 ± 26.5

57.61 ± 22.6

49.12 ± 6.1

34.77 ± 1.2

34.63 ± 0.1

52.23 ± 44

MCV (10^−15L)

52.03 ± 3.6

51.58 ± 5.1

51.05 ± 2.93

51.97 ± 2.9

52.43 ± 0.9

53.20 ± 3.9

51.53 ± 4.1

49.35 ± 4.1

49.35 ± 1.8

50.27 ± 3.6

51.67 ± 2.6

51.73 ± 7.8

MCH (10^-12g)

18.87 ± 1.3

17.63 ± 1.0

17.53 ± 0.6

19.28 ± 0.6

19.80 ± 0.1

22.10 ± 3.7

19.40 ± 2.9

17.63 ± 1.0

17.50 ± 0.7

19.08 ± 0.4

19.23 ± 0.3

21.53 ± 3.9

PLT (10^9/L)

239.6 ± 34.6

129.0 ± 26

247.3 ± 27.5

173.5 ± 23.1

260.7 ± 42.3

195.6 ± 76.3

264.8 ± 47.3

120.8 ± 22.1

267.1 ± 11.5

184.2 ± 20

265.3 ± 76

217.0 ± 20

ALT (U/L)

59.0 ± 0.7

87.5 ± 30.5

69.17 ± 29.9

76.17 ± 24.6

59.67 ± 27.5

64.00 ± 43

51.25 ± 0.9

70.50 ± 20.3

68.33 ± 27

75.3 ± 29.4

59.2 ± 24.1

57.33 ± 41

ALP (U/L)

232.79 ± 3.9

234.00 ± 3.8

247.6 ± 14.8

249.3 ± 27.5

248.3 ± 13.8

249.2 ± 14.2

232.21 ± 4.9

238.17 ± 5.7

246.6 ± 15.9

247.3 ± 15

246.1 ± 13

247.6 ± 17

*The Nu-3 concentration was 100 mg/ml. The data were expressed as average ±SD.